Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Muscle-invasive Urothelial Cancer of the Bladder”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT02989584
What this trial is testing

A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer

Who this might be right for
Bladder CancerMetastatic Bladder CancerUrothelial Carcinoma
Memorial Sloan Kettering Cancer Center 54
Testing effectiveness (Phase 2)Study completedNCT03617913
What this trial is testing

Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer

Who this might be right for
Bladder Carcinoma Infiltrating the Muscle of the Bladder WallStage II Bladder Cancer AJCC v8Stage II Renal Pelvis Cancer AJCC v8+9 more
Mayo Clinic 2
Testing effectiveness (Phase 2)Study completedNCT04919512
What this trial is testing

TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder

Who this might be right for
Urinary Bladder Neoplasms
Janssen Research & Development, LLC 163
Not applicableStudy completedNCT02657486
What this trial is testing

BGJ398 in Non-Muscle-Invasive Urothelial Carcinoma of the Bladder

Who this might be right for
Bladder CancerNon-Muscle-Invasive Urothelial Carcinoma
Memorial Sloan Kettering Cancer Center 4
Testing effectiveness (Phase 2)Ended earlyNCT04871529
What this trial is testing

Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL)

Who this might be right for
Bladder Carcinoma Infiltrating the Muscle of the Bladder WallInfiltrating Renal Pelvis and Ureter Urothelial CarcinomaStage II Bladder Cancer AJCC v8
SWOG Cancer Research Network 6
Testing effectiveness (Phase 2)UnknownNCT05495724
What this trial is testing

Disitamab Vedotin Combined With Tislelizumab for Her2 Overexpressing High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable

Who this might be right for
Her2 Overexpressing High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma
Tianjin Medical University Second Hospital 176
Early research (Phase 1)WithdrawnNCT04073160
What this trial is testing

TRIO Bladder: A Study of Durvalumab Plus Tremelimumab Followed by Concurrent Durvalumab Plus Bladder Radiation in Muscle-Invasive Bladder Cancer

Who this might be right for
Bladder Cancer
Daniel George, MD
Large-scale testing (Phase 3)Looking for participantsNCT07720284
What this trial is testing

An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC

Who this might be right for
High-risk Muscle Invasive Urothelial Carcinoma
AstraZeneca 915
Large-scale testing (Phase 3)Active Not RecruitingNCT02951325
What this trial is testing

Bladder Cancer Adjuvant Radiotherapy Trial

Who this might be right for
Bladder CancerUrothelial Carcinoma Bladder
Tata Memorial Centre 153
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07356791
What this trial is testing

Phase II Prospective Cohort Study of Intravesical Recombinant Human Type 5 Adenovirus Injection for Treatment of High-Risk Non-Muscle Invasive Bladder Cancer: Evaluating Efficacy and Safety

Who this might be right for
Bladder (Urothelial, Transitional Cell) Cancer
RenJi Hospital 18
Testing effectiveness (Phase 2)Looking for participantsNCT07647289
What this trial is testing

EV + Toripalimab vs GC as Neoadjuvant Therapy in Locally Advanced/High-Risk MIBC

Who this might be right for
Muscle-Invasive Bladder Cancer (MIBC)
Peking University Third Hospital 58
Not applicableStudy completedNCT04617743
What this trial is testing

The Effect of Post-voiding Reisdual Urine on Non-muscle Invasive Bladder Cancer Recurrence and Progression

Who this might be right for
Bladder Cancer RecurrentNon-Invasive Bladder Urothelial Carcinoma
Istanbul Medeniyet University 500
Not applicableStudy completedNCT05154084
What this trial is testing

RESECT: Improving Quality in TURBT Surgery.

Who this might be right for
Bladder Cancer
British Urology Researchers in Surgical Training 19,505
Large-scale testing (Phase 3)Ended earlyNCT04197986
What this trial is testing

Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations

Who this might be right for
Upper Tract Urothelial CarcinomasUrothelial Bladder Cancer
QED Therapeutics, a BridgeBio company 39
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06528483
What this trial is testing

Bladder Preservation With Sacituzumab Govitecan + Zimberelimab for Muscle-Invasive Bladder Cancer

Who this might be right for
Bladder CancerBladder Urothelial CarcinomaBladder Neoplasm+1 more
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 63
Testing effectiveness (Phase 2)Looking for participantsNCT06809140
What this trial is testing

Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer

Who this might be right for
Muscle Invasive Bladder Urothelial Carcinoma
Matthew Galsky 75
Testing effectiveness (Phase 2)UnknownNCT04730232
What this trial is testing

Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable

Who this might be right for
High-RiskNon-Muscle Invasive Bladder Urothelial Carcinoma
Tianjin Medical University Second Hospital 63
Testing effectiveness (Phase 2)Study completedNCT00045630
What this trial is testing

S0219, Combination Chemotherapy Followed By Observation or Surgery in Patients With Stage II or Stage III Cancer of the Urothelium

Who this might be right for
Bladder CancerTransitional Cell Cancer of the Renal Pelvis and UreterUrethral Cancer
SWOG Cancer Research Network 77
Large-scale testing (Phase 3)Not Yet RecruitingNCT07464145
What this trial is testing

NDV-01 (Sustained-release Gemcitabine-docetaxel) in Participants With Non-muscle Invasive Bladder Cancer

Who this might be right for
Bladder (Urothelial, Transitional Cell) CancerBladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)Urothelial Carcinoma Bladder+2 more
Relmada Therapeutics, Inc. 393
Testing effectiveness (Phase 2)Study completedNCT00749892
What this trial is testing

Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer

Who this might be right for
Recurrent Bladder Urothelial CarcinomaRecurrent Renal Pelvis Urothelial CarcinomaRecurrent Ureter Urothelial Carcinoma+17 more
M.D. Anderson Cancer Center 34
Next Page